Practice Management Seminar in January 2018 by Florida Allergy, Asthma & Immunology Society (FAAIS)

Announcement from the Florida Allergy, Asthma & Immunology Society (FAAIS):

SAVE THE DATE – Registration Information coming in the next 2 weeks! Register with FAAIS for updates:

Are you overwhelmed with the burdens of the ever-changing healthcare landscape that affects our specialty?

Are you spending too much time on internal administration issues that constrict your work-flow and take away time from patient care?

Do feel that you can do better with reimbursement and collections?

You are not alone and FAAIS is here for you!

We are thrilled to announce:

Inaugural Florida Allergy, Asthma & Immunology Society Practice Management Seminar
January 27-28, 2018 at the Rosen Centre Hotel in Orlando, Florida!

This meeting is an exceptionally high-yield and efficiently-paced course for physicians and office managers about topics that directly affect all allergy practices. The lectures will be given by nationally-recognized experts who have spoken many times at the national allergy meetings. While the lectures are didactic, careful attention and time will be devoted to answer your specific questions. There will be additional time for interaction with colleagues, speakers and vendors over the course of the weekend.

The Seminar will address the following Allergy-specific topics:

· Coding and Billing updates for the Allergist, Basic and Advanced
· MACRA/MIPS for the Allergist
· Revenue Cycle Management including Collections
· How to Optimize Office Operations
· Human Resource Topics
· Avoiding Legal Pitfalls
· Update on Regulatory Compliance and much more to come…

Target Audience: New and established allergists/immunologists, office managers, administrators and fellows-in-training.


$299 for FAAIS members and their administrators
$499 for non-members
$149 for fellows-in-training
This is a Non- CME/CE Seminar

Program Directors: Thomas Lupoli, DO and Patrick DeMarco, MD, MBA

Hope to see you there!! Watch your emails for registration and hotel information soon!!!

Jeanne Torbett, CMP, CMMM
Executive Director
Florida Allergy, Asthma & Immunology Society

phone: 904-765-7702
fax: 904-765-7767

4909 Lannie Road, Ste. B
Jacksonville, FL 32218

Cetirizine Eye Drops for Allergic Conjunctivitis - Zerviate 1 drop twice daily

The US Food and Drug Administration (FDA) approved the first topical ocular formulation of the antihistamine cetirizine for the treatment of ocular itching associated with allergic conjunctivitis.
The efficacy of cetirizine ophthalmic solution 0.24% (Zerviate) was shown in 3 clinical trials.

Patients had less ocular itching within 15 minutes and the effect persisted for 8 hours after treatment.

In PR-focused wording, the company quotes cetirizine "world-wide exposure representing more than 300 million patient-years".

The recommended dose of Zerviate is one drop in each affected eye twice daily, 8 hours apart.

The most commonly reported adverse reactions were ocular hyperemia (redness), instillation site pain, and reduction in visual acuity, which occurred in roughly 1% to 7% of patients.

Treatment options for allergic conjunctivitis (eye drops) (click here for larger image).


FDA Clears Cetirizine Eye Drops for Allergic Conjunctivitis

Histaminergic Angioedema

Angioedema is frequently categorized into:

- histamine-mediated disease
- bradykinin-mediated disease

It is critical to determine the underlying mediator of symptoms as it directs treatment.

Histaminergic angioedema is the most frequent cause of angioedema. It is classified as:

- acute (lasting less than 6 weeks)
- chronic (symptoms for longer than 6 weeks)

It is further classified into angioedema presenting with or without urticaria.

Mast cells and basophils are central to the underlying pathophysiology of histamine-mediated angioedema.

The underlying treatments of histamine-mediated angioedema are:

- antihistamines
- corticosteroids
- epinephrine


Histaminergic Angioedema

Acquired C1 Inhibitor Deficiency (C1-INH-AAE)

Acquired angioedema due to C1-INH deficiency (C1-INH-AAE) can occur when there are acquired (not inherited) deficiencies of C1-INH.

A quantitative or functional C1-INH deficiency with negative family history and low C1q is diagnostic of C1-INH-AAE.

The most common conditions associated with C1-INH-AAE are:

- autoimmunity
- B-cell lymphoproliferative disorders

A diagnosis of C1-INH-AAE can precede a diagnosis of lymphoproliferative disease and confers an increased risk for developing non-Hodgkin lymphoma.

Treatment focuses on symptom control with:

- therapies that regulate bradykinin activity (C1-INH concentrate, icatibant, ecallantide, tranexamic acid, androgens)
- treatment of any underlying conditions


Acquired C1 Inhibitor Deficiency

Acute Management of Hereditary Angioedema Attacks (HAE)

Several treatment modalities have become available for management of acute hereditary angioedema (HAE) attacks in the last 15 years. Preferred contemporary use of the treatments is “on demand,” because control remains with the patient and delays in treatment access avoided.

Four treatments are available:

— plasma-derived C1 inhibitor concentrate
- recombinant C1 inhibitor concentrate
- ecallantide
- icatibant


Acute Management of Hereditary Angioedema Attacks
Blog Widget by LinkWithin